Mikhail Blagosklonny of Oncotarget is proud to have sponsored the Ride for Roswell in Buffalo, New York for the past two years. For those who don’t know, Mikhail Blagosklonny of Oncotarget explains that the Ride for Roswell is one of America’s largest charitable cycling events. The annual charitable bike ride brings people together to celebrate cancer survivors, pay tribute to cancer victims who have lost their lives and work together to raise money to find a cure. Over its 24-year history, The Ride for Roswell has generated more than $50 million in cancer research donations. The 2019 race raised more than $5.5 million.
Mikhail Blagosklonny of Oncotarget points out that the most powerful moment of the event happens before the ride even begins. Every bicyclist lifts a card with a name of a patient currently battling cancer inside Roswell Park hospital. The symbolism of the signs creates an emotional bond that joins patients looking down from the hospital windows, survivors, riders and every person in attendance whose family understands the world of cancer. While the riders may not be able to see the patients through the window on a sunny afternoon, there’s no denying their presence.
The funds raised from The Ride for Roswell each year go directly to the Roswell Park Alliance Foundation. This not-for-profit organization is one Misha Blagosklonny of Oncotarget believes in strongly. They get the money directly to support cutting-edge cancer research and boost the patient-care programs offered at Roswell Park hospital. Thanks to the incredible donors, Roswell Park Hospital is not only a leading cancer facility in the state of New York but a leading cancer facility in the United States. Misha Blagosklonny is not only a proud sponsor of the event, but he’s a proud member of the Roswell Park Cancer Institute as a Professor of Oncology at the Roswell Park Center Institute. Mikhail Blagosklonny of Oncotarget has seen first-hand what monetary donations can contribute to in the fight for a cancer cure. Since coming to Roswell Park Comprehensive Cancer Center in 2009, Mikhail Blagosklonny has studied the prevention of cancer thanks in large part to the contributions of donors. Misha Blagosklonny has led research on inhibiting organism aging, in other words, “preventing cancer by staying young”. His laboratory conducted research on the suppression of cellular senescence, using different mTOR inhibitors (rapamycin is one of them). The cell culture studies were complemented by studies in mice. Mikhail Blagosklonny has also published extensively on those topics, especially focusing on combination of anti-aging drugs to be used in humans. Please check his blog for more information. https://www.mikhailblagosklonny.com/rapamycin-time-is-now-unless-its-too-late/